Compare VIAV & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIAV | GKOS |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.7B |
| IPO Year | 1996 | 2015 |
| Metric | VIAV | GKOS |
|---|---|---|
| Price | $47.66 | $161.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $61.43 | ★ $198.69 |
| AVG Volume (30 Days) | ★ 4.9M | 723.5K |
| Earning Date | 10-28-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,518,300,000.00 | $507,442,000.00 |
| Revenue This Year | $24.56 | $36.18 |
| Revenue Next Year | $13.18 | $23.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.03 | 32.33 |
| 52 Week Low | $12.23 | $73.16 |
| 52 Week High | $60.43 | $191.62 |
| Indicator | VIAV | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 73.52 | 44.37 |
| Support Level | $44.41 | $148.39 |
| Resistance Level | $54.68 | $184.68 |
| Average True Range (ATR) | 2.13 | 6.29 |
| MACD | 1.33 | 0.38 |
| Stochastic Oscillator | 95.73 | 47.75 |
Viavi Solutions Inc is a world-wide leader in test and measurement and optical technologies. Its test and measurement, and resilient Position, Navigation and Timing (PNT) solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, it develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets. The company's segments are Network and Service Enablement (NSE); and Optical Security and Performance Products (OSP). Majority of revenue comes from NSE segment. It has presence in Americas, Asia-Pacific, and EMEA. Majority of revenue is from America.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.